US Stock MarketDetailed Quotes

CTOR Citius Oncology

Watchlist
  • 0.940
  • -0.080-7.84%
Close Mar 7 16:00 ET
  • 0.966
  • +0.026+2.77%
Post 20:01 ET
67.26MMarket Cap-2.91P/E (TTM)

Citius Oncology Key Stats

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q1)Dec 31, 2024
(FY)Sep 30, 2024
(Q1)Dec 31, 2023
(FY)Sep 30, 2023
(FY)Sep 30, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
0
126.35K
0
0
0
Net income from continuing operations
-40.86%-6.66M
-66.56%-21.15M
---4.73M
-133.72%-12.7M
---5.43M
Deferred tax
83.50%264.24K
0.00%576K
--144K
0.00%576K
--576K
Change In working capital
72.01%4.59M
29.98%13.2M
--2.67M
109.11%10.16M
--4.86M
-Change in inventory
---6.11M
---2.13M
--0
--0
----
-Change in prepaid assets
--0
78.19%-1.1M
--0
-409.47%-5.04M
---990.18K
-Change in payables and accrued expense
301.26%10.7M
8.12%16.43M
--2.67M
159.98%15.2M
--5.85M
Cash from discontinued investing activities
Operating cash flow
--0
--126.35K
--0
--0
--0
Investing cash flow
Cash flow from continuing investing activities
-5M
0
Net intangibles purchase and sale
----
---5M
----
--0
----
Cash from discontinued investing activities
Investing cash flow
----
---5M
----
--0
----
Financing cash flow
Cash flow from continuing financing activities
4.87M
0
Net issuance payments of debt
----
--3.8M
----
--0
----
Net other financing activities
----
--1.07M
----
----
----
Cash from discontinued financing activities
Financing cash flow
----
--4.87M
----
--0
----
Net cash flow
Beginning cash position
--112
--0
--0
--0
--0
Current changes in cash
----
--112
----
----
----
End cash Position
--112
--112
--0
--0
--0
Free cash flow
--0
---4.87M
--0
--0
--0
Currency Unit
USD
USD
USD
USD
USD
Audit Opinions
--
Unqualified Opinion with Explanatory Notes
--
--
--
(Q1)Dec 31, 2024(FY)Sep 30, 2024(Q1)Dec 31, 2023(FY)Sep 30, 2023(FY)Sep 30, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities 0126.35K000
Net income from continuing operations -40.86%-6.66M-66.56%-21.15M---4.73M-133.72%-12.7M---5.43M
Deferred tax 83.50%264.24K0.00%576K--144K0.00%576K--576K
Change In working capital 72.01%4.59M29.98%13.2M--2.67M109.11%10.16M--4.86M
-Change in inventory ---6.11M---2.13M--0--0----
-Change in prepaid assets --078.19%-1.1M--0-409.47%-5.04M---990.18K
-Change in payables and accrued expense 301.26%10.7M8.12%16.43M--2.67M159.98%15.2M--5.85M
Cash from discontinued investing activities
Operating cash flow --0--126.35K--0--0--0
Investing cash flow
Cash flow from continuing investing activities -5M0
Net intangibles purchase and sale -------5M------0----
Cash from discontinued investing activities
Investing cash flow -------5M------0----
Financing cash flow
Cash flow from continuing financing activities 4.87M0
Net issuance payments of debt ------3.8M------0----
Net other financing activities ------1.07M------------
Cash from discontinued financing activities
Financing cash flow ------4.87M------0----
Net cash flow
Beginning cash position --112--0--0--0--0
Current changes in cash ------112------------
End cash Position --112--112--0--0--0
Free cash flow --0---4.87M--0--0--0
Currency Unit USDUSDUSDUSDUSD
Audit Opinions --Unqualified Opinion with Explanatory Notes------
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.